According to reports by World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries and ranks third or fourth in further 23 countries. The International Agency for Research on Cancer presented an estimate of 19.3 million new cancer cases every year along with 10.0 million cancer deaths in 2020. Data shows that breast cancer (in females) has surpassed lung cancer as the most commonly diagnosed cancer in the world. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
Recently, an experiment was being carried out on some cancer patients and it is hoped that the result of this experiment will bring a ray of hope to the lives of other cancer patients. This experimental treatment brought relief to 18 patients as they became completely free from rectal cancer. It is notable that these patients were suffering from stage 2 and stage 3 rectal cancer. The patients represented a special variant of rectal cancer with genetic mutations with mismatched repair deficiency. The body of such patients tend to respond less to chemotherapy and radiotherapy, which increases the need for surgery to get the tumour removed.
All these 18 patients were involved in the clinical trial of an anti-cancer drug named Dostarlimab, every three weeks in six months. At the end of the experiment, all the patients witnessed a miraculous relief in their bodies as the cancerous tumours in their body seemed to disappear. During the trials, the progress of medicine was being regularly assessed by various means. After the end of the trial, the patients had to go through tests like endoscopy, positron emission tomography which confirmed the zero presence of any kind of cancer cells in the body.
Dostarlimab is sold under the brand name "Jemperli" and is an immunotherapy drug used in the treatment of endometrial cancer. This was the first clinical trial which was carried out on humans to test its potentialities.Dostarlimab is a drug with laboratory-produced molecules. The molecules act as substitute antibodies in the human body. It can also be said that it is a medicine which detects the causes of cancer in the body and helps in treating them, which in-turn, helps in improving the body's immunity. The best part of this medicine is that it has no side effects.
Dostarlimab is sold under the brand name "Jemperli" and is an immunotherapy drug used in the treatment of endometrial cancer. This was the first clinical trial which was carried out on humans to test its potentialities.
Medical Officer cum In-Charge of the Department of Cancer Registry and Epidemiology at the Dr B Borooah Cancer Institute in Guwahati, Dr Krishnatreya in this aspect added that this research is good as it will provide relief to the patients but it is also important to know that different bodies react differently to every medicine. Even the researchers should take some more time to carry out more experiments instead of arriving at a direct conclusion after carrying out a trial only on a few people. Dr Krishnatreya has over six years of working and research experience in the field of cancer registry and epidemiology. Dr Krishnatreya has over 40 publications in national and international medical journals.